Skip to main content
. 2021 Sep 3;30(11):2136–2139. doi: 10.1158/1055-9965.EPI-21-0476

Table 1.

Demographic characteristics of SEER-Medicare pancreatic cancer cases and frequency-matched controls 1992–2015a.

Pancreatic cancer casesb
Controls First primary Later primaries All primaries
(N = 320,296) (N = 61,081) (N = 18,993) (N = 80,074)
Characteristics n (%) n (%) n (%) n (%)
Age at diagnosis or selection, years
 66–69 42,388 (13.2) 8,590 (14.1) 2,007 (10.6) 10,597 (13.2)
 70–74 71,148 (22.2) 13,979 (22.9) 3,808 (20.0) 17,787 (22.2)
 75–79 75,692 (23.6) 14,253 (23.3) 4,670 (24.6) 18,923 (23.6)
 80–84 66,048 (20.6) 12,140 (19.9) 4,372 (23.0) 16,512 (20.6)
 85–89 43,496 (13.6) 7,991 (13.1) 2,883 (15.2) 10,874 (13.6)
 90–94 17,524 (5.5) 3,357 (5.5) 1,024 (5.4) 4,381 (5.5)
 95–99 4,000 (1.2) 771 (1.3) 229 (1.2) 1,000 (1.2)
Sex
 Men 144,484 (45.1) 26,277 (43.0) 9,844 (51.8) 36,121 (45.1)
 Women 175,812 (54.9) 34,804 (57.0) 9,149 (48.2) 43,953 (54.9)
Race/ethnicity
 Non-Hispanic white 264,161 (82.5) 49,619 (81.2) 16,171 (85.1) 65,790 (82.2)
 Non-Hispanic black 23,841 (7.4) 6,179 (10.1) 1,705 (9.0) 7,884 (9.8)
 Non-Hispanic Asian 14,483 (4.5) 2,176 (3.6) 442 (2.3) 2,618 (3.3)
 Hispanic 7,893 (2.5) 1,227 (2.0) 237 (1.2) 1,464 (1.8)
 Other/missing 9,918 (3.1) 1,880 (3.1) 438 (2.3) 2,318 (2.9)
Calendar year of diagnosis or selection
 1992–2000 61,352 (19.2) 12,382 (20.3) 2,956 (15.6) 15,338 (19.2)
 2001–2005 73,460 (22.9) 14,279 (23.4) 4,086 (21.5) 18,365 (22.9)
 2006–2009 71,592 (22.4) 13,537 (22.2) 4,361 (23.0) 17,898 (22.4)
 2010–2015 113,892 (35.6) 20,883 (34.2) 7,590 (40.0) 28,473 (35.6)
Months of coverage, median (IQR)
 Part A/B/non-HMO 67 (42–82) 71 (42–84) 74 (48–85) 72 (43–84)
 Part D 18 (0–52) 17 (0–48) 15 (0–49) 16 (0–49)
Average physician visits/6 months, median (IQR) 3.0 (1.3–5.5) 3.1 (1.4–5.8) 4.3 (2.3–7.1) 3.4 (1.5–6.1)
Low-income subsidy/Medicaid eligibility
 Ever 37,034 (11.6) 6,695 (11.0) 1,720 (9.1) 8,415 (10.5)
 Never 130,922 (40.9) 24,398 (39.9) 9,176 (48.3) 33,574 (41.9)
 Unknown 152,340 (47.6) 29,988 (49.1) 8,097 (42.6) 38,085 (47.6)
Co-morbidities diagnoses
 Overweight or obesity 17,980 (5.6) 4,113 (6.7) 1,398 (7.4) 5,511 (6.9)
 Smoking behavior-relatedc 23,803 (7.4) 5,787 (9.5) 2,472 (13.0) 8,259 (10.3)
 Chronic obstructive pulmonary disease 59,294 (18.5) 12,734 (20.8) 4,705 (24.8) 17,439 (21.8)
 Alcohol-relatedd 14,294 (4.5) 4,102 (6.7) 1,475 (7.8) 5,577 (7.0)
 Acute or chronic pancreatitis 3,609 (1.1) 1,685 (2.8) 591 (3.1) 2,276 (2.8)
 Type 2 diabetes mellitus 90,232 (28.2) 21,993 (36.0) 7,149 (37.6) 29,142 (36.4)
Hemochromatosis 653 (0.2) 137 (0.2) 49 (0.3) 186 (0.2)
Sideroblastic anemia 993 (0.3) 192 (0.3) 108 (0.6) 300 (0.4)
Congenital dyserythropoietic anemia 1,375 (0.4) 262 (0.4) 136 (0.7) 398 (0.5)
NACLD 3,316 (1.0) 791 (1.3) 311 (1.6) 1,102 (1.4)
 Liver cirrhosis 1,113 (0.3) 279 (0.5) 105 (0.6) 384 (0.5)
 Fatty liver disease 1,503 (0.5) 359 (0.6) 146 (0.8) 505 (0.6)

Abbreviations: HMO, health maintenance organizations; IQR, interquartile range; NACLD, non–alcoholic-related chronic liver disease; SEER, Surveillance, Epidemiology, and Ends Results Program.

aControls were frequency matched to the pancreatic cancer cases by age category (66–69. 70–74, 75–79, 80–84, 85–89, 90–94, and 95–99), sex, and calendar year of diagnosis. International Classification of Diseases – 9th edition included: hemochromatosis (275.0, 275.01, and 275.03), sideroblastic (285.0), and congenital dyserythropoietic (285.8) anemias and NACLD (571.4, 571.41, 571.42, 571.49, 571.5, 571.6, 571.8, and 571.9).

bFirst primary pancreatic cancer was defined as pancreatic cancer occurring as a first malignancy and later primaries pancreatic cancer were defined as primary pancreatic cancer occurring as second or third malignancy between 1992 and 2015.

cAny personal history of tobacco use or nondependent tobacco use disorder.

dAny diagnosis of alcohol-induced liver disorders, alcohol-induced psych/neurologic disorders, alcohol intoxication, nondependent alcohol abuse, or personal history of alcoholism.